25 February 2026 - Commercial launch expected on 9 March 2026.

Eton Pharmaceuticals today announced the US FDA approval of a new drug application for Desmoda (desmopressin acetate) oral solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency, as antidiuretic replacement therapy for patients of all ages.

Read Eton Pharmaceuticals press release